Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
USE CASES
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
PatSnap Eureka Desktop
NEWAnalytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
NEWServices professionnels
Cabinets d'avocats
Sciences de la vie
Haute technologie
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport ASOs, gene therapy, and small molecules in the DMD drug pipeline: patent landscape, key assignees, and emerging modalities from exon-skipping to AAV microdystrophin.
Article | Rapport How optical neural networks use photonic chips to slash AI training energy costs — from 10 mW phase modulators to terabit-per-second weight encoding.
Article | Rapport Mapping the 2026 solid-state electrolyte patent landscape: oxide, sulfide, polymer, and composite SSE clusters, key assignees, and five emerging directions shaping next-gen batteries.
Article | Rapport Mapping the 2026 solid-state electrolyte patent landscape: material families, key assignees, emerging architectures, and strategic IP implications for ASSB development.
Article | Rapport A 2026 patent landscape of implantable neural interface technology: electrode materials, wireless power, closed-loop stimulation, and BCI signal processing trends.
Article | Rapport How does Intel's RibbonFET compare to TSMC's GAA nanosheet at 2nm? A patent-backed technical breakdown of channel geometry, SRAM design, and CFET roadmaps.
Article | Rapport A deep-dive patent landscape of implantable neural interface technology in 2026: electrode materials, wireless power, closed-loop stimulation, and BCI architectures.
Article | Rapport How complement alternative pathway inhibitors—ASOs, gene therapy, antibodies, and proteases—are reshaping treatment of geographic atrophy and C3 glomerulopathy.
Article | Rapport BTK inhibitors are reshaping CNS lymphoma and neuroinflammation treatment. Explore the patent pipeline, resistance mechanisms, and combination strategies in this deep-dive analysis.
Article | Rapport How RNAi, CRISPR base editing, and LNP delivery are reshaping liver-targeted gene silencing for NASH, HBV, TTR amyloidosis, and dyslipidemia. Patent landscape analysis.
Article | Rapport GCase activation, Rab1a microautophagy, LRRK2 inhibitors, PINK1/Parkin mitophagy, and gene therapy: a patent-driven analysis of the PD lysosomal-autophagy pipeline.
Article | Rapport How GLP-1 mono, dual, and triple agonist strategies are reshaping the NASH drug pipeline — patent signals, key assignees, and emerging combination approaches.
Article | Rapport PROTACs, ASOs, and immunotherapy approaches for tau clearance in Alzheimer's and PSP: phosphoepitope antibodies, peptide vaccines, degraders, and biomarker-guided sequencing.
Article | Rapport KRAS mutations drive up to 95% of pancreatic and ~45% of colorectal cancers. Explore the patent landscape, inhibitor strategies, and emerging combination approaches.
Article | Rapport How antisense oligonucleotides, gene therapy, C5aR antagonists, and fusion proteins are reshaping the complement-targeting therapy landscape in GA and C3G.